Altimmune, Inc. - Common Stock (NQ:ALT)

5.380 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist

Price and Volume

Volume	159,916
Open	5.380
Bid (Size)	5.450 (6,000)
Ask (Size)	5.480 (100)
Prev. Close	5.380
Today's Range	5.380 - 5.380
52wk Range	2.900 - 7.730
Shares Outstanding	95,598,665
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗

Today 4:13 EST

Retail sentiment on Stocktwits for SPY and QQQ remained ‘bearish’.

Via Stocktwits

ALT Stock Rallies 4% — What Does Retail Think? ↗

January 22, 2026

Earlier this month, Altimmune said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide for the treatment of patients with metabolic...

Via Stocktwits

Performance

YTD	+53.3%	+53.3%
1 Month	+34.5%	+34.5%
3 Month	+35.9%	+35.9%
6 Month	+30.9%	+30.9%
1 Year	-22.5%	-22.5%

More News

Why Are Investors Looking At Altimmune Stock? ↗

January 05, 2026

Via Benzinga

Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗

January 05, 2026

Via Stocktwits

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗

December 19, 2025

Via Stocktwits

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗

November 17, 2025

Via Stocktwits

Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

October 16, 2025

From Grabar Law Office

Via GlobeNewswire

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

October 10, 2025

Via Benzinga

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 08, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

October 06, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

October 06, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 06, 2025

Via NewMediaWire

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 06, 2025

Via TheNewswire.com

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

October 05, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm

October 03, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 03, 2025

Via NewMediaWire

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 03, 2025

Via TheNewswire.com

Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)

October 01, 2025

Via NewMediaWire

Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)

October 01, 2025

Via TheNewswire.com

ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT

September 30, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT

September 30, 2025

From DJS Law Group

Via Business Wire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

September 30, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

DEADLINE APPROACHING: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025

September 30, 2025

From Berger Montague

Via GlobeNewswire

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

September 30, 2025

Via NewMediaWire

Frequently Asked Questions

Is Altimmune, Inc. - Common Stock publicly traded?

Yes, Altimmune, Inc. - Common Stock is publicly traded.

What exchange does Altimmune, Inc. - Common Stock trade on?

Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Altimmune, Inc. - Common Stock?

The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market

What is the current price of Altimmune, Inc. - Common Stock?

The current price of Altimmune, Inc. - Common Stock is 5.380

When was Altimmune, Inc. - Common Stock last traded?

The last trade of Altimmune, Inc. - Common Stock was at 01/22/26 04:00 PM ET

What is the market capitalization of Altimmune, Inc. - Common Stock?

The market capitalization of Altimmune, Inc. - Common Stock is 514.32M

How many shares of Altimmune, Inc. - Common Stock are outstanding?

Altimmune, Inc. - Common Stock has 514M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.